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Naive T cells undergo metabolic reprogramming to
support the increased energetic and biosynthetic
demands of effector T cell function. However, how
nutrient availability influences T cell metabolism and
function remains poorly understood. Here we report
plasticity in effector T cell metabolism in response
to changing nutrient availability. Activated T cells
were found to possess a glucose-sensitive metabolic
checkpoint controlledby theenergysensorAMP-acti-
vated protein kinase (AMPK) that regulated mRNA
translation and glutamine-dependent mitochondrial
metabolism to maintain T cell bioenergetics and
viability. T cells lacking AMPKa1 displayed reduced
mitochondrial bioenergetics and cellular ATP in
response to glucose limitation in vitro or pathogenic
challenge in vivo. Finally, we demonstrated that
AMPKa1 is essential for T helper 1 (Th1) and Th17
cell development and primary T cell responses to viral
and bacterial infections in vivo. Our data highlight
AMPK-dependent regulation of metabolic homeo-
stasis as a key regulator of T cell-mediated adaptive
immunity.
INTRODUCTION
T lymphocytes are central effectors of the adaptive immune
response, and their function is critical for long-lasting immunity
to foreign pathogens. While T cell activation initiates specific
transcriptional programs that direct T cell differentiation and
effector function, the regulation of cellular metabolism is also in-
tegrated into the T cell activation program (MacIver et al., 2013;
Wang and Green, 2012b). Upon activation, naive T cells shift to-ward a pro-growth metabolic program characterized by
increased glucose and amino acid metabolism (Carr et al.,
2010; Frauwirth et al., 2002; Nakaya et al., 2014; Sinclair
et al., 2013; Wang et al., 2011). The predominant metabolic
phenotype of activated CD4+ and CD8+ T effector (Teff) cells
in vitro is a shift to aerobic glycolysis (Michalek et al., 2011a),
also known as the ‘‘Warburg Effect.’’ Transcription factors
including Myc (Wang et al., 2011), estrogen-related receptor a
(ERRa) (Michalek et al., 2011b), and the liver X receptors
(LXRs) (Bensinger et al., 2008) facilitate T cell metabolic reprog-
ramming by enhancing the expression of metabolic genes
downstream of TCR signaling, which allow Teff cells to meet
the bioenergetic and biosynthetic requirements of cell division
and effector function.
Nutrient availability can have a profound effect on T cell activa-
tion and function. Limiting glucose or glutamine in culture me-
dium decreases the activation of naive T cells and subsequent
T cell proliferation (Ardawi and Newsholme, 1983; Brand, 1985;
Carr et al., 2010; Jacobs et al., 2008; Wang et al., 2011). Conse-
quently, reduced nutrient availability during early activation
impairs interferon-g (IFN-g) production by CD4+ and CD8+ Teff
cells in vitro (Cham et al., 2008; Cham and Gajewski, 2005;
Chang et al., 2013). Recent work indicates that the development
and function of Teff cells in vivo can be influenced by changes in
nutrient transport (Macintyre et al., 2014; Nakaya et al., 2014;
Sinclair et al., 2013). However, the mechanisms by which
T cells couple changes in nutrient availability to immunologic
function remain poorly understood. This is an important issue,
as effective adaptive immunity requires Teff cells to expand,
survive, and maintain effector function in a range of microenvi-
ronments, including sites of infection or inflammation where
nutrients and oxygen might be limiting (McNamee et al., 2013;
Sitkovsky and Lukashev, 2005). Here we examined the impact
of nutrient availability on Teff cell metabolism and function. We
provide evidence for plasticity in T cell metabolic reprogram-
ming, a process regulated by the energy sensor AMP-activated
protein kinase (AMPK).Immunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc. 41
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Figure 1. Glucose Limitation Induces a Metabolic Checkpoint in T Cells
(A) Schematic of T cell culture protocol.
(B) IFN-g profiles for 3 day activated CD8+ Teff cells re-stimulated under the indicated glucose concentrations.
(C) MFI of IFN-g for cytokine producing cells in (B).
(D) Immunoblot for mTORC1 activity (total and phosphorylated S6 kinase [S6K], ribosomal protein S6 [rpS6] and total 4EBP1) in Teff cells cultured for 5 hr with or
without glucose (Glc) or glutamine (Q).
(E) IFN-g production by CFSE-labeled CD8+ Teff cells cultured with (+) or without () glucose for 5 hr or re-fed with 25 mM glucose for 1 hr (+Glc addback, right
panel). Numbers indicate the percentage of IFN-g+CD8+ T cells in each culture condition.
(F) Viability of CFSE-labeled Teff cells after culture in complete or glucose-free (Glc) medium for 5 hr (percentage of dead cells are indicated).
(G) ATP content of Teff cells after incubation in glucose-free medium for the indicated times. ATP concentration was expressed relative to ATP levels in Teff cells
grown under full glucose conditions.
(H–J) Cellular bioenergetics of glucose-starved Teff cells. (H) ECAR and OCR for CD8+ Teff cells cultured for 5 hr in medium containing the indicated
concentrations of glucose. (I) OCR:ECAR ratio and (J) SRC for CD8+ Teff cells cultured in the presence (+) or absence () of glucose for 5 hr. *p < 0.05; **p < 0.01;
***p < 0.001.RESULTS
Glucose Limitation Induces a Metabolic Checkpoint in
T Cells
In many cell types, nutrient limitation induces ametabolic check-
point that limits cell proliferation and growth when resources are
scarce. Thus, we investigated the relationship between nutrient
availability, effector function, and metabolism in activated Teff
cells. CD4+ or CD8+ Teff cells were generated via anti-CD3
and anti-CD28 antibody stimulation with interleukin-2 (IL-2) for
3 days, followed by acute glucose starvation (Glc) for 5 hr prior42 Immunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc.to characterization (Figure 1A). Overnight glucose starvation
slowed the proliferation of both CD4+ and CD8+ Teff cells
(Figure S1A). Activated CD8+ Teff cells re-stimulated under
decreasing levels of glucose displayed a dose-dependent
decrease in IFN-g production (Figure 1B). Reducing glucose
concentrations below 25 mM (standard concentration in
IMDM) decreased both the percentage of IFN-g+ CD8+ T cells
(Figure 1B) and the mean fluorescence intensity (MFI) of IFN-g
staining for IFN-g+ cells (Figure 1C). This decrease in IFN-g pro-
tein production was not due to decreased transcription of Ifng
mRNA (Figure S1B).
A central regulator of T cell mRNA translation and effector
function is the mammalian target of rapamycin complex 1
(mTORC1) (Powell and Delgoffe, 2010; Zeng and Chi, 2013).
Withdrawal of either glucose or glutamine suppressed mTORC1
activity in activated T cells, as measured by reduced phosphor-
ylation of the mTORC1 targets S6K, rpS6, and 4E-BP1 (Fig-
ure 1D). Total S6K protein was also reduced in T cells starved
of glucose or glutamine (Figure 1D).
We next assessed whether the effect of glucose availability on
T cell cytokine production was reversible. CD8+ Teff cells were
starved of glucose for 5 hr, followed by re-introduction of
25 mM glucose for 1 hr, and IFN-g production by Teff cells
wasmeasured by flow cytometry. While glucose withdrawal pro-
moted a 5-fold reduction in the frequency of IFN-g+ CD8+ T cells,
re-introduction of glucose for 1 hr restored the ability of glucose-
starved Teff cells to produce IFN-g (Figure 1E). Teff cell viability
was maintained during this culture period despite acute removal
of glucose (Figure 1F).
Finally, we examined the effect of glucose availability on T cell
metabolism. Cellular ATP concentrations were maintained in
T cells after acute glucose starvation (Figure 1G). To explore
this further, we cultured Teff cells for 5 hr under various glucose
concentrations, and assessed their bioenergetic profiles via
Seahorse assay (Wu et al., 2007). The extracellular acidification
rate (ECAR), a measure of extracellular pH that positively co-re-
lates with glycolysis in lymphocytes (Chang et al., 2013),
decreased in CD8+ T cells as glucose concentration decreased,
despite the presence of IL-2 to drive glycolysis (Figure 1H). In
parallel, we examined the mitochondrial O2 consumption rate
(OCR), a measure of OXPHOS. We found that mitochondrial
OCR was maximal in CD8+ T cells at lower glucose concentra-
tions (1.5–6 mM), and largely maintained under glucose-free
conditions (Figure 1H). This translated as a progressive increase
in the OCR:ECAR ratio as glucose concentrations decreased
(Figure S1C). Both CD8+ and CD4+ T cells demonstrated a sharp
decline in ECAR while increasing their OCR:ECAR ratio under
glucose-free conditions (Figures 1H and 1I and S1D and S1E),
consistent with previous results (Chang et al., 2013; Sukumar
et al., 2013).
Mitochondrial spare respiratory capacity (SRC) is defined as
the increase in OCR following uncoupling with FCCP (van der
Windt et al., 2012). SRC is the maximum oxidative potential of
the mitochondria available for energy production, and is linked
with increased bioenergetic advantage in T cells during recall re-
sponses andmetabolic stress (van derWindt et al., 2012; van der
Windt et al., 2013). Glucose starvation promoted an increase in
SRC in Teff cells (Figures 1J and S1E). Together these data indi-
cate that T cells display flexibility in their metabolic reprogram-
ming in response to changing glucose availability.
Glutamine Supports TCellMetabolismunderConditions
of Glucose Limitation
Given that ATP concentrations are maintained in glucose-
starved Teff cells despite reduced glycolysis, we hypothesized
that Teff cells engage alternate metabolic pathways to maintain
cellular bioenergetics. The non-essential amino acid glutamine is
critical for activation-induced T cell proliferation (Carr et al.,
2010; Wang et al., 2011) and is used in many cell types to fuel
oxidative metabolism under stress conditions (Le et al., 2012;Yang et al., 2009). Glutamine withdrawal reduced the OCR of
Teff cells despite the continued presence of glucose (Fig-
ure S2A), resulting in a decreased OCR:ECAR ratio (Figure 2A).
Glutamine withdrawal had only a minor effect on the ECAR of
Teff cells (Figure S2A). However, unlike glucose, glutamine was
required to maintain ATP concentrations in Teff cells (Figure 2B).
The expression of genes involved in glutamine metabolism,
including the glutamine transporters Snat1 and Snat2 and gluta-
minase (Gls), increased significantly in Teff cells under glucose
withdrawal (Figure 2C), while glycolytic gene expression was
largely unaffected (Figure S2B).
We next conducted stable isotope tracer analysis (SITA) with
[U-13C]-glutamine to assess whether glutamine metabolism in
T cells was altered by glucose availability (schematic in Fig-
ure S2C). Teff cells were acutely starved of glucose, followed
by culture for an additional hour with [U-13C]-glutamine (in
glucose-free medium), and 13C incorporation in metabolite pools
was quantified by GC-MS. This approach allowed us to measure
the incorporation of 13C label into lactate and TCA cycle metab-
olites as they are approaching steady-state labeling (Figure S2D).
Total concentrations of [U-13C]-glutamine-derived glutamate
were elevated in glucose-starved Teff cells (Figure 2D), while
similar concentrations of 13C enrichment were observed in suc-
cinate, fumarate, and malate between control and glucose-
starved Teff cells (Figure 2E), indicating that glutamine-derived
TCA cycle metabolites were maintained in glucose-starved Teff
cells. In contrast, Teff cells starved of glutamine displayed a
depletion of TCA cycle intermediates that could not be compen-
sated by glucose (Figure S2E). Citrate concentrations decreased
under glucose deprivation (Figure 2E), which might reflect the
reduced contribution of glucose to the citrate pool. The distribu-
tion of mass isotopomers in [U-13C]-glutamine-derived TCA
cycle metabolites was not dramatically affected by glucose
availability (Figure S2F).
Glucose-derived pyruvate is an important source of acetyl-
CoA, which is a key carbon input into the TCA cycle (Owen
et al., 2002). Conventional formation of malate from [U-13C]-
glutamine in the TCA cycle will generate malate m+4. However,
decarboxylation of glutamine-derived malate (or OAA) will
generate pyruvate m+3 due to the loss of one carbon as CO2
(Figure S2C). If the latter pathway is active, condensation of
[U-13C]-glutamine-derived acetyl-CoAm+2 (fromPDH-mediated
decarboxylation of pyruvate m+3) with [U-13C]-glutamine-
derived OAA (m+4) is predicted to generate citrate m+6 (Fig-
ure S2C). Interestingly, we found that the proportion of pyruvate
m+3 increased specifically in glucose-starved Teff cells (Figures
2F and S2F). Similarly, citrate m+6 was generated only in Teff
cells deprived of glucose (Figures 2G and S2F). Finally, activated
Teff cells that are normally resistant to acute glucose withdrawal
(Figure 1F) displayed increased levels of cell death when both
glucose and glutamine were absent from the culture medium
(Figure 2H). Collectively, these data highlight a central role for
glutamine in maintaining T cell metabolism and viability.
AMPKRegulates TCell Effector Function in Response to
Nutrient Availability
AMPK is a central regulator of cellular responses to metabolic
stress (Hardie et al., 2012) and is activated in CD8+ T cells during
primary responses in vivo (Pearce et al., 2009). Similar toImmunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc. 43
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Figure 2. Glutamine Supports T Cell Metabolism under Conditions of Glucose Limitation
(A) OCR:ECAR ratio for Teff cells cultured for 5 hr under control (+Q, white) or glutamine-free (Q, gray) conditions.
(B) ATP concentrations in Teff cells after culture in glutamine-free medium (Q) for the indicated times. Data are expressed relative to ATP concentrations in Teff
cells grown with 4 mM glutamine.
(C) Expression of glutamine metabolism genes by CD8+ Teff cells cultured with (+) or without () glucose for 5 hr. Data are expressed as the log2 of fold changes
from CD8+ Teff cells grown in complete medium (n = 3 mice per condition).
(D) Relative abundance of 13C-labeled (black) or unlabeled (white) glutamate in Teff cells following culture with (+) or without () glucose (Glc) for 5 hr, followed by
1 hr incubation with medium containing 2mM [U-13C]-Q. Metabolite abundances were determined by GC-MS, and expressed as the mean ± SEM for triplicate
samples.
(E) Relative abundance of 13C-labeled (black) or unlabeled (white) TCA cycle intermediates citrate, succinate, fumarate, and malate for Teff cells treated as in (D).
(F andG)Mass isotopomer distribution of [U-13C]-glutamine-derived carbon into pyruvate and citrate. Teff cells were cultured as in (D) and the percent distribution
of m+3 pyruvate (F) and m+6 citrate (G) determined by GC-MS. The data represent the percent abundance of the indicated isotopomers for their respective
metabolite pool.
(H) CD8+ Teff cell viability following culture with (+) or without () glucose (Glc) or glutamine (Q) for 12 hr. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3. AMPK Regulates T Cell Effector Function in Response to Nutrient Availability
(A) Immunoblot for AMPK activation (total and phospho-AMPKa) and mTORC1 activation (total and phospho-S6K) in wild-type (+/+) or Prkaa1-deficient (/)
T cells cultured with or without glucose (Glc) or glutamine (Q) for 5 hr.
(B) Proliferation of CFSE-labeled Prkaa1+/+ and Prkaa1/ CD4+ T cells 3 days after stimulation with aCD3 and aCD28 antibodies plus irradiated splenocytes in
medium containing the indicated glucose concentrations.
(C) IFN-g production by Prkaa1+/+ or Prkaa1/CD8+ Teff cells re-stimulated with PMA and ionomycin in medium containing 25 or 5mM glucose. The percentage
of IFN-g+ cells (of total CD8+ cells) and the MFI of IFN-g staining are indicated.
(D) IFN-g production by control Prkaa1+/+ or Prkaa1/ CD8+ Teff cells following treatment with AICAR (2 mM) or Phenformin (Phen, 2 mM).
(E) Schematic of experimental setup for polysomal fractionation.
(F) Teff cells were treated as in (E) and cell lysates sedimented on 10% to 50% sucrose gradients. Displayed is the relative absorbance (A) at 254 nm for RNA
fractions collected from Teff cells cultured in 25 mM (black) or 0 mM (red) glucose. Monosome (M) and polysome (P) fractions are indicated. Inset, the polysome-
to-monosome ratio (P:M) for Teff cells cultured in 25mM (black) versus 0 mM (red) glucose.
(G) Quantitative RT-PCR (qPCR) for Ifng and Il2mRNAs associated withmonosome (M) and polysome (P) fractions. Total mRNAwas purified from each fraction in
(F) and qPCR for mRNAs was performed on the indicated fractions. Data are presented as the percentage of mRNA in each fraction of the total RNA pool.
(H) P:M ratio for Prkaa1+/+ (white) or Prkaa1/ (black) T cells restimulated under 25 or 5 mM glucose conditions.
(I)Prkaa1+/+ (white) orPrkaa1/ (black) Teff cells were cultured in 5mMglucose and total RNA isolated from fractions were analyzed for Ifng expression by qPCR.
Data are presented as in (G) for biological triplicate samples.previous results (Rolf et al., 2013), Thr-172 phosphorylation of
the AMPKa subunit in T cells was increased by either glucose
or glutamine deprivation (Figure 3A). S6K phosphorylation was
elevated in AMPKa1-deficient (Prkaa1/) Teff cells relative to
control Teff cells and remained elevated when cells were
cultured in medium lacking glucose or glutamine (Figure 3A).
Although control and AMPKa1-deficient T cells displayed similar
proliferation rates under full glucose (25 mM) conditions,
Prkaa1/ T cells displayed reduced proliferation when stimu-
lated under low glucose concentrations (3–6 mM) (Figure 3B).T cell viability between genotypes was not affected during these
short culture periods (Figure S3A).
We next assessed the effect of glucose availability on cytokine
production by Prkaa1/ T cells. We observed an increased per-
centage of IFN-g-producing CD8+ T cells in Prkaa1/ T cell cul-
tures, as well as an increase in the MFI of IFN-g for Prkaa1/
cytokine-producing T cells (Figure 3C). Reducing extracellular
glucose to physiological concentrations (5 mM) decreased both
the percentage of IFN-g+ CD8+ T cells and the MFI of cytokine-
producing T cells in control cultures, while Prkaa1/ CD8+Immunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc. 45
T cells displayed greater resistance to suppression of IFN-g pro-
duction by glucose limitation (Figure 3C). AMPK activation was
sufficient to suppress IFN-g production by Teff cells, as acute
treatment with the AMPK agonists AICAR or phenformin (Phen)
suppressed IFN-g production by wild-type but not Prkaa1/
CD8+ Teff cells (Figures 3D and S3B and S3C). Notably, AICAR
and phenformin treatment acutely suppressed the percentage
of IFN-ghi CD8+ T cells in culture (Figures S3B and S3C).
Given that IfngmRNA levels in Teff cells were not significantly
affected by glucose availability (Figure S1B), one possibility for
the reduced staining intensity of IFN-g in glucose-starved
T cells was the differential translation of IfngmRNA, whichwe as-
sessed by polysome fractionation (Figure 3E). Polysome profiles
of Teff cells cultured under glucose-free versus full glucose
conditions revealed a reduction in the polysome fraction and
decrease in the polysome-to-monosome (P:M) ratio in
glucose-starved Teff cells (Figure 3F), indicative of reduced
mRNA translation (Jaramillo et al., 2011). The majority of Ifng
mRNA in Teff cells cultured under high-glucose conditions was
associated with heavy polysome fractions (fractions 14 and
above), indicating active translation of this transcript (Figure 3G,
top panel). Glucose withdrawal promoted a shift in Ifng mRNA
from heavy to light polysome fractions in Teff cells (Figure 3G),
consistent with reduced translation of Ifng mRNAs. Similar re-
ductions in the percentage of Il2 (Figure 3G, bottom panel) and
Gapdh (Figure S3D) mRNAs associated with heavy polysome
fractions were observed in glucose-starved Teff cells.
We next examined the polysome profiles of Prkaa1+/+ and
Prkaa1/ Teff cells grown under high (25 mM) or low (5 mM)
glucose concentrations. Prkaa1/ Teff cells maintained a higher
P:M ratio than control Teff cells under low glucose conditions
(Figure 3H), and a greater percentage of Ifng mRNA remained
associated with heavy polysome fractions in AMPKa1-deficient
T cells under glucose starvation conditions (Figure 3I). mRNA
transcripts for Gapdh were similarly enriched in polysomes
from glucose-starved Prkaa1/ Teff cells (Figure S3E).
AMPK Regulates Metabolic Adaptation in Activated
T Cells
We next examined the influence of AMPK on Teff cell meta-
bolism. Under standard growth conditions, Prkaa1/ Teff cells
displayed a modest increase in OCR relative to control T cells,
but no difference in ECAR (Figure S4A). Glucose starvation
induced a large drop in ECAR for both control and Prkaa1/
T cells (Figure S4B). However, both the OCR (Figure 4A) and
SRC (Figure 4B) of Prkaa1/ T cells were significantly reduced
by glucose withdrawal compared to control Teff cells. Analysis
of adenylate concentrations by LC-MS revealed a decreased
ATP:AMP ratio in AMPKa1-deficient T cells, which decreased
further under glucose withdrawal (Figure 4C). Notably, ATP con-
centrations were largely maintained in control T cells upon
glucose withdrawal, but decreased by 50% in Prkaa1/ Teff
cells, whereas AMP concentrations were elevated in Prkaa1/
T cells regardless of glucose concentration (Figure S4C).
Given the dependence of OXPHOS, mitochondrial respiratory
capacity, and ATP maintenance on AMPKa1 expression in Teff
cells, we next assessed the impact of AMPKa1 loss on Teff
cell metabolic reprogramming. Prkaa1/ Teff cells failed to up-
regulate the expression of genes involved in glutamine meta-46 Immunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc.bolism upon glucose withdrawal and maintained expression of
glucosemetabolism genes includingGlut1 and Ldha (Figure 4D).
The conversion of glutamine to glutamate, which is enhanced
in Teff cells by glucose withdrawal (Figure 2D), was lower in
glucose-starved Prkaa1/ Teff cells (Figures 4E and S4D).
Moreover, the total amount of glutamine-derived TCA cycle in-
termediates (including citrate, succinate, fumarate, and malate)
was lower in Prkaa1/ Teff cells upon glucose starvation (Fig-
ures 4F and S4D). The distribution of mass isotopomers in
[U-13C]-glutamine-derived metabolites was similar between
control and Prkaa1/ Teff cells (Figure S4E). However,
Prkaa1/ Teff cells displayed lower abundance of [U-13C]-gluta-
mine-derived pyruvate m+3 (Figure 4G) and citrate m+6 (Fig-
ure 4H) under conditions of glucose limitation. Finally, Prkaa1/
CD4+ and CD8+ Teff cells displayed increased cell death in
response to glucose withdrawal (Figure 4I). Together, these
data indicate that AMPKa1 is required to support pathways of
glutamine metabolism engaged by T cells to maintain cellular
bioenergetics and T cell survival.
AMPK Is Required for the Accumulation of Th1 and Th17
Cells and Development of Colitis In Vivo
We next assessed the function of Prkaa1/ T cells in vivo
through a series of adoptive transfer experiments. Loss of
AMPKa1 did not affect the ability of naive T cells to expand
in vivo, as both CD4+ and CD8+ T cells from Prkaa1/mice un-
derwent homeostatic proliferation in Rag2/ hosts (Figure 5A).
We next adoptively transferred naive CD4+CD25 T cells sorted
from Prkaa1+/+ or Prkaa1/ mice into T cell-deficient (Tcrb/)
or Rag2/ mice, and the presence of inflammatory donor
CD4+ T cells in the colonic lamina propria (cLP) and mesenteric
lymph nodes (mLNs) was measured 3 weeks later (Figure S5A).
Loss of AMPKa1 did not impair the differentiation of donor-
derived CD4+ T cells into Th1 (IFN-g+) or Th17 (IL-17+) lineage
cells in Tcrb/ mice, as the frequency of Th1 or Th17 cells in
the cLP and mLN was similar between animals that received
control or Prkaa1/ CD4+ T cells (Figures 5B and S5B). Consis-
tent with our in vitro data linking AMPKa1 to suppression of cyto-
kine mRNA translation (Figure 3C), the MFI of IFN-g staining for
IFN-g+CD4+ T cells infiltrating the cLP was significantly higher
in Prkaa1/ donor CD4+ T cells (Figures 5C and 5D). However,
the total number of CD4+ T lymphocytes recovered from the
mLN and cLP of recipient mice was lower in animals that
received Prkaa1/ CD4+ T cells (Figure S5C). This translated
into a 5-fold reduction in the total number of inflammatory Th1
or Th17 cells in the mLN and cLP of mice that received naive
Prkaa1/ CD4+ T cells (Figure 5E). Histologic analysis of colon
specimens revealedmoderate-to-severe colitis inmice receiving
wild-type donor CD4+ T cells, marked by globet cell loss and se-
vere mononuclear infiltration into the mucosa and extension into
the muscularis and serosa (Figure 5F). In contrast, the colons of
mice that received Prkaa1/ CD4+ T cells showed almost no
colitis with intact epithelial structures and reduced inflammatory
infiltrate (Figures 5F and 5G).
AMPK Is Required for Effective Primary T Cell
Responses to Viral and Bacterial Infections
We next investigated the role of AMPK in T cell-mediated im-
mune responses to viral and bacterial infections in vivo using
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Figure 4. AMPK Regulates Metabolic Adaptation in Activated T Cells
(A and B)Prkaa1+/+ (white) orPrkaa1/ (black) Teff cells were subject to glucosewithdrawal for 5 hr, and theOCR (A) and SRC (B) determined by Seahorse assay.
OCR in (A) was expressed relative to the OCR of Teff cells grown in glucose-replete conditions.
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(D) Expression of glucose and glutaminemetabolism genes in Prkaa1+/+ orPrkaa1/ T cells grown under glucosewithdrawal. Data are expressed as the log2 fold
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Prkaa1fl/fl, hereafter referred to as KO-T). We first assessed pul-
monary T cell-mediated immune responses by infecting KO-Tmice and control littermates (WT-T) with a sub-lethal dose
(50 PFU) of influenza A virus (IAV) (Figure S6A) (Coulombe
et al., 2014; Jaworska et al., 2014). At day 9 post-infectionImmunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc. 47
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Figure 5. AMPK Is Required for the Accu-
mulation of CD4+ Th1 and Th17 Cells In Vivo
(A) CFSE dilution profiles of Prkaa1+/+ (black line)
and Prkaa1/ (gray histogram) T cells 5 days
following adoptive transfer into Rag2/ mice.
(B) IFN-g and IL-17A staining for donor CD4+ cells
isolated from the mLNs or cLP of recipient mice
3 weeks post transfer.
(C) IFN-g production by donor Prkaa1+/+ (white) or
Prkaa1/ (black) CD4+ cells in the cLP. Numbers
indicate the percentage of IFN-g+CD4+ donor cells
isolated from the cLP.
(D) MFI of IFN-g staining for IFN-g+ donor CD4+
T cells in (C).
(E) Total number of Prkaa1+/+ (white) or Prkaa1/
(black) Th1 (CD4+IFNg+) and Th17 (CD4+IL-17+)
cells isolated from the mLN and cLP of Tcrb/
mice 3 weeks post-transfer.
(F) Representative H&E staining of colon sections
from Tcrb/ mice receiving naive Prkaa1+/+ or
Prkaa1/ CD4+ T cells 3 weeks post adoptive
T cell transfer.
(G) Pathology scoring of colon sections from
recipient mice. *p < 0.05; **p < 0.01; ***p < 0.001.(dpi), the total number of leukocytes was reduced in the bron-
choalveolar lavage (BAL), lungs and mediastinal lymph node
(LN) of IAV-infected KO-T mice compared to littermate controls
(Figure S6B). The frequency and total number of T cells was
lower in the BAL and lungs of KO-T mice (Figure S6C), which
was associated with decreased frequency and total numbers
of CD4+ and CD8+ T cells (Figures 6A and S6D). In addition,
the frequency and total number of CD8+ T cells specific for the
immunodominant IAV nucleoprotein (NP) epitope was reduced
in the BAL (Figure 6B) and lungs (Figure S6E) of IAV-infected
KO-T mice. In IAV-infected WT-T and KO-T mice, the frequency
of pulmonary T cells producing IFN-gwas similar following stim-
ulation with whole UV-inactivated IAV, hemagglutinin (HA) pep-
tide (specific for CD4+ T cells), or NP peptide (specific for
CD8+ T cells) at day 9 or 12 post-infection (Figures 6C and 6D,
left panels). However, consistent with the reduced T cell
numbers in infected KO-Tmice, there was a reduction in the total
number of IFN-g-producing CD4+ and CD8+ T cells in the BAL of
IAV-infected KO-T mice relative to control animals (Figures 6C
and 6D, right panels). Considering the quantity and quality of48 Immunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc.innate immunity (including macrophages)
is intact in KO-T mice, we observed no
difference in pulmonary viral load during
early phases of infection (Figure 6E).
We next investigated the role of
AMPK in T cell-mediated immune re-
sponses to the Gram-positive bacterium
L. monocytogenes (Lm) by infecting con-
trol and KO-T mice with a variant of Lm
expressing OVA (rLmOVA) (Krawczyk
et al., 2007) (Figure S7A). KO-T mice dis-
played a reduced number of OVA-spe-
cific CD8+ T cells 7 days post infection
with rLmOVA compared to control litter-
mates (Figures 7A and 7B). Similar toinfection with IAV, KO-T mice displayed a reduction in total
CD4+ and CD8+ T cell numbers following rLmOVA infection rela-
tive to controls (Figure S7B). The reduction in OVA-specific
T cells was not due to delayed kinetics of expansion, as mice
with conditional deletion of AMPKa1 displayed a lower percent-
age of OVA-specific T cells over the course of infection (Fig-
ure 7C). Re-stimulation of splenocytes from day 7 infected
mice in vitro revealed a reduction in the number of IFN-g+CD8+
(Figures 7D-E) and IFN-g+CD4+ (Figure S7C) T cells in KO-T
mice. At 3 dpi, bacterial load was elevated in the liver of infected
KO-T mice compared to control animals and a similar trend was
also observed in the spleens of infected mice (Figure S7D),
suggesting reduced pathogen clearance in KO-Tmice. No differ-
ence in the percentage of splenic CD8+CD44hiCD62Llo (acti-
vated or Tem) cells was observed between genotypes, although
there was a slight increase in the number of CD8+CD44hiCD62Lhi
(Tcm) cells in the spleens of some KO-T mice (Figure S7E).
CD44 expression on OVA-specific CD8+ T cells (Kb/SIINFEKL)
was similar between genotypes (Figure S7F), while CD8+Kb/
SIINFEKL T cells from KO-T mice displayed lower KLRG1
AB D
E
C
Figure 6. AMPKa1 Is Required for Primary T Cell Responses to Pulmonary Influenza A Viral Infection
(A) Total number of CD4+ and CD8+ T cells (CD45.2+CD19CD3+) in the BAL (left) and lungs (right) of control (WT-T) and T cell AMPKa1-deficient (KO-T) mice
9 days post infection (dpi).
(B) Flow cytometry analysis of IAV H-2Db-NP+CD8+ T cells in the BAL of WT-T and KO-T mice at 9 dpi. Numbers indicate the percentage of CD8+ T cells stained
with NP-loadedH-2Db tetramer (NPTet). The frequency and total number of IAVH-2Db-NP+CD8+ T cells in the BAL ofWT-T and KO-Tmice at day 9 post-infection
are indicated.
(C and D) The frequency (left panel) and total number (right panel) of Ag-specific IFN-g+ CD4+ (C) and CD8+ (D) T cells from the BAL of infected WT-T and KO-T
mice at 9 and 12 dpi was determined by ICS following 10 hr stimulation with UV-inactivated IAV (1 MOI), 5 mg/ml IAV HA110–120 or IAV NP366–374 peptides.
(E) Viral load in the lungs of infected WT-T and KO-T mice 3 and 6 dpi. All data are expressed as the mean ± SEM for 4–5 mice/group. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.expression (Figure S7G), suggesting a reduced number of short-
lived effector cells (SLECs) in these animals.
To examine the importance of AMPKa1 on the survival of acti-
vated T cells in vivo, we adoptively transferred equal numbers of
in vitro activated CD8+OT-I+ T cells isolated from either WT-T or
KO-T (Ly5.2+) mice into recipient congenic hosts (Ly5.1+) that
had been infected with wild-type Lm to generate an inflamma-
tory, but antigen-irrelevant environment. The number of KO-T
OT-I+Ly5.2+ donor cells recovered from the spleens of recipient
mice was lower than that of AMPKa1-expressing control cells
(Figure 7F), indicating reduced survival of AMPKa1-deficient
CD8+ T cells in inflammatory environments in vivo.
Finally, we assessed whether the genetic ablation of Raptor,
a scaffolding protein for mTORC1 (Laplante and Sabatini,2009), in T cells would rescue the defect in primary responses
by AMPKa1-deficient T cells in vivo. Deletion of Raptor failed
to reverse the phenotype of AMPKa1-deficient T cells, as mice
harboring T cell specific deletion of both AMPKa1 and Raptor
(DKO-T) failed to generate OVA-specific (Figures S7H and S7I)
or IFN-g-producing (Figure S7J) CD8+ T cells after infection
with rLmOVA.
AMPKa1-Deficient Teff Cells Display Reduced
Metabolic Activity In Vivo
To examine whether the reduced ability of AMPKa1-deficient
T cells to adapt to metabolic perturbations in vitro was linked
to impaired generation of Teff cells in vivo we examined the
metabolic profile of Teff cells from KO-T animals followingImmunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc. 49
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Figure 7. AMPKa1 Is Required for Primary T Cell Responses to L. monocytogenes
(A and B) Control (WT-T) and T cell AMPKa1-deficient (KO-T) mice were infected with rLmOVA, and splenocytes analyzed for antigen-specific responses 7 dpi.
The percentage (A) and total number (B) of OVA-Tetramer (Kb/OVA)-positive CD8+ T cells in spleens of infected mice at 7 dpi are indicated (WT-T, n = 6; KO-T,
n = 5).
(C) The percentage of CD8+Kb/OVA+ T cells in peripheral blood was measured over time following infection of WT-T and KO-T mice with rLmOVA.
(D and E) Splenocytes from rLmOVA-infected mice were stimulated with OVA peptide 7 dpi, and IFN-g production by CD8+ T cells assessed by ICS. (D) CD44
versus IFN-g staining for CD8+ T cells. (E) Total numbers of CD8+IFN-g+ T cells.
(F) WT-T and KO-T OT-I T cells (Ly5.2+) were activated in vitro for 3 days, followed by adoptive transfer (63 106 cells/mouse) into Ly5.1+ congenic hosts infected
with wild-type Lm three days prior. Recovery of surviving CD8+OT-I+Ly5.2+ T cells in the spleens of recipient mice 3 days post transfer are shown.
(legend continued on next page)
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pathogenic challenge. WT-T and KO-T mice were infected with
rLmOVA (as in Figure S7A), and activated CD8+ Teff cells
(CD44hiCD62Llo) were isolated 7 dpi and subjected to bioener-
getic profiling ex vivo (Figures 7G–7I). CD8+ Teff cells isolated
from LmOVA-infected KO-Tmice displayed reduced basal mito-
chondrial OCR relative to control T cells (Figure 7G). Moreover,
the maximal mitochondrial oxidative capacity (Figure 7H) and
SRC (Figure 7I) of AMPKa1-deficient Lm-specific CD8+ Teff cells
were reduced relative to control Teff cells.
To assess the impact of AMPKa1 on T cell metabolic reprog-
ramming in vivo, we examined metabolic gene expression in Teff
cells isolated from rLmOVA-infected mice. Teff cells from KO-T
mice displayed reduced expression of glucose (Glut1, Ldha)
and glutamine (Snat1, Snat2, Gls, Got1, Gpt1) metabolism genes
(Figure 7J). We next measured glucose uptake by Teff cells
in vivo using the fluorescent glucose analog 2-NBDG (O’Sullivan
et al., 2014). While larger than conventional glucose due to its
fluorescent tag, 2-NBDG is actively transported into cells similar
to D-glucose and can be used to image glucose uptake in live
cells (O’Neil et al., 2005). WT-T and KO-T mice were infected
with rLmOVA, injected with 2-NBDG 7 dpi and 2-NBDG uptake
by CD8+Kb/ SIINFEKL+ T cells in vivo was assessed by flow cy-
tometry. 2-NBDG uptake by antigen-specific CD8+ T cells from
KO-T mice was 30% lower relative to WT-T cells (Figure 7K).
Finally, we measured ATP concentrations in CD8+ T cells sorted
from rLmOVA-infected mice (7 dpi). No difference in ATP con-
centrations was observed for naive T cells (CD44loCD62Lhi) of
each genotype (Figure 7L). However, ATP concentrations were
higher in Teff cells (CD44hiCD62Llo) from WT-T mice, while ATP
concentrations in KO-T CD8+ Teff cells were similar to naive
T cells (Figure 7L). Together, these data indicate that AMPKa1
is required to maintain the metabolic homeostasis of Teff cells
in vivo.
DISCUSSION
Much of our understanding of T cell metabolism is based on the
metabolic programs engaged by Teff cells in vitro. Under these
conditions, where nutrient availability is in excess relative to
normal physiological concentrations, glycolytic metabolism
(i.e., the Warburg effect) is a dominant metabolic program in
Teff cells. However, our results indicated that Teff cells are
capable of adapting their metabolism in response to reduced
glucose availability, even in the presence of TCR-mediated
metabolic reprogramming that favors glycolytic metabolism.
We found that Teff cells actively engage glutamine-dependent
OXPHOS to maintain ATP concentrations and cell viability
under low glucose conditions. The energy sensor AMPK played
a key role in this metabolic adaptation. AMPKa1-deficient
T cells displayed reduced metabolic plasticity in response to(G–I) Bioenergetic profile of Lm-specific Teff cells ex vivo. CD44hiCD62Llo CD8+ T
OCR profile following addition of mitochondrial inhibitors (oligomycin, FCCP, rot
mined by Seahorse analysis (n = 3 per genotype).
(J) Expression of glucose and glutamine metabolism genes by WT-T and KO-T CD
the log2 fold change relative to naive control (CD44lowCD62Lhi) CD8+ T cells isol
(K) In vivo 2-NBDG uptake by CD8+Kb/OVA+ cell fromWT-T and KO-Tmice 7 dpi. L
T cells. Right panel, quantification of 2-NBDG MFI for T cells isolated from indivi
(L) ATP content of CD8+ naive (Tn) and Teff cells isolated from rLmOVA-infectedglucose limitation in vitro, and reduced metabolic activity
and lower ATP levels during pathogenic challenge in vivo. The
reversible metabolic checkpoint induced in lymphocytes is
reminiscent of AMPK function in tumor cells, where AMPK trig-
gers a cell cycle checkpoint to maintain cell viability under poor
nutrient conditions (Jones et al., 2005). We speculate that
T cells display metabolic flexibility to help preserve cell viability
and effector function in the face of varying environmental
conditions.
Energetic homeostasis can be achieved by increasing ATP
production or reducing energy expenditure. Our data suggested
that Teff cells engage both strategies to adapt to glucose
limitation. We found that T cells actively dampened energy-
consuming processes including cell proliferation and cytokine
production when nutrients were low. IFN-g production was high-
ly sensitive to glucose availability. Shifting Teff cells to physiolog-
ical glucose concentrations (5 mM) promoted a significant
decrease in IfngmRNA translation and overall IFN-g production.
AMPK acts as a key regulator of this process by suppressing
cytokine mRNA translation under conditions of reduced glucose
availability. Stimulation of AMPK activity by AICAR or phenfor-
min actively suppressed IFN-g production by Teff cells, while
AMPKa1-deficient Teff cells appeared locked in a pro-growth
state marked by increased IFN-g production, even when meta-
bolic conditions were unfavorable.
Conversely, we found that T cells actively engaged alternate
pathways of ATP production to maintain T cell energetic homeo-
stasis under conditions of metabolic stress. Glutamine-depen-
dent OXPHOS was essential for maintaining T cell energetic
homeostasis, as removal of glutamine promoted the rapid
depletion of both TCA cycle intermediates and cellular ATP in
Teff cells, even when glucose was readily available. These data
argue against theWarburg effect as the main metabolic program
for ATP production in activated T cells. Glucose starvation
triggered an AMPKa1-dependent shift in Teff cell metabolic re-
programming by increasing the expression of genes involved in
glutamine uptake and glutaminolysis (i.e., Snat1, Snat2, Gls). In
addition, our SITA experiments indicate that T cells with low
glycolytic flux can engage a novel metabolic shunt involving
the conversion of glutamine to pyruvate. Engaging this metabolic
shunt allows glucose-starved T cells to maintain a pool of pyru-
vate, derived from glutamine rather than glucose, which can be
converted to acetyl-CoA and maintain TCA cycle homeostasis,
similar to adaptive strategies used by glucose-starved tumor
cells (Le et al., 2012; Yang et al., 2009). AMPK activity is required
for these processes, as AMPKa1-deficient T cells are less able to
engage glutamine oxidation to compensate for loss of glycol-
ysis-derived ATP.
To date, the role of AMPK in T cell function has been contro-
versial. T cells isolated from whole body AMPKa1-deficientcells from WT-T (white) and KO-T (black) mice were sorted 7 dpi, and the (G)
enone/antimycin A), (H) maximal mitochondrial OCR, and (I) SRC were deter-
8+ Teff cells isolated from rLmOVA-infected mice 7 dpi. Data are expressed as
ated from rLmOVA-infected mice (n = 3 per genotype).
eft panel, representative histogram of 2-NBDG fluorescence for CD8+Kb/OVA+
dual mice (n = 5 per genotype).
WT-T and KO-T mice 7 dpi. *p < 0.05; **p < 0.01; ***p < 0.001.
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mice display normal responses to mitogenic stimulation in vitro
(MacIver et al., 2011; Mayer et al., 2008), while impaired central
memory T cell (Tcm) generation has been reported using an inde-
pendent T cell-specific AMPKa1-deleted mouse strain (Rolf
et al., 2013). These data are in sharp contrast with the murine
model of whole-body AMPKa1 deletion, which leads to the accu-
mulation of activated CD8+ T cells (MacIver et al., 2011) and
exacerbated T cell-mediated pathology in an in vivo model of
autoimmunity (Nath et al., 2009). Using three distinct in vivo
model systems, we provide evidence that AMPKa1 is required
for primary T cell responses in vivo. Loss of AMPKa1 did not
affect the differentiation of naive CD4+ T cells into Th1 or Th17
cells in immunodeficient mice; rather, the total number of inflam-
matory Prkaa1/ CD4+ Teff cells that developed in recipient
mice was dramatically reduced, leading to reduced develop-
ment of T cell-mediated colitis. Similarly, the expansion of anti-
gen-specific CD8+ T cells in response to viral (IAV) or bacterial
(rLmOVA) infection was reduced in animals lacking AMPKa1
expression in T cells, despite the fact that AMPKa1-deficient
T cells displayed normal TCR-stimulated proliferation in vitro
and homeostatic proliferation in vivo. The reduced number of
AMPKa1-deficient Teff cells observed in all three model systems
may reflect a failure of Teff cells to persist or survive in inflamma-
tory microenvironments. In support of this, AMPKa1-deficient
Teff cells displayed increased sensitivity to apoptosis when
faced with nutrient limitation in vitro or inflammatory environ-
ments in vivo.
Our data point to AMPK-dependent control of T cell meta-
bolism as a key determinant of T cell effector responses. While
AMPKa1-deficient T cells displayed a lower ATP:AMP ratio rela-
tive to control T cells, AMPKa1 was not required for TCR-medi-
ated proliferation or metabolic programming when glucose
was in excess. Rather, AMPK was required to modulate T cell
metabolism and effector function when glucose was scarce.
Under low glucose conditions, Prkaa1/ T cells displayed
reduced levels of glutamine-dependent OXPHOS and were un-
able to maintain cellular ATP levels, leading to increased bioen-
ergetic deficit and cell death. Similarly, AMPKa1-deficient Teff
cells displayed reduced metabolic gene expression, lower
glucose uptake, and reduced OXPHOS and mitochondrial SRC
in response to pathogenic challenge in vivo. SRC represents
increased mitochondrial electrochemical potential, which can
be used to generate ATP, and is a key index of T cell metabolic
fitness (Pearce and Pearce, 2013; van der Windt et al., 2012).
Impaired nutrient utilization and reduced SRC may explain the
failure of AMPKa1-deficient Teff cells to maintain cellular ATP
concentrations, survive metabolic challenges in vitro, andmount
robust effector responses in vivo.
Overall, our study provides evidence that T cells have evolved
a rapid nutrient-sensing system that influences the metabolic
fitness of responding Teff cells in vivo. This metabolic check-
point—regulated by the energy sensor AMPK—ultimately influ-
ences the size (cell number) and strength (cytokine production)
of the T cell response. We hypothesize that this intrinsic system
evolved to maintain mitochondrial function and cellular energy
levels in T cells to support the viability and phenotypic stability
of Teff cells in microenvironments where O2 and nutrients might
be limiting. This raises the possibility that other metabolic sen-
sors, such as HIF-1a (Wang and Green, 2012a) or mTOR (Powell52 Immunity 42, 41–54, January 20, 2015 ª2015 Elsevier Inc.and Delgoffe, 2010; Zeng and Chi, 2013), might regulate T cell
effector function through similar effects on T cell bioenergetics.
In this regard, AMPK agonists, such as metformin or A-769662
(Vincent et al., 2014), might provide new ways to shape T cell-
mediated immune responses by altering T cell metabolism and
mitochondrial function.
EXPERIMENTAL PROCEDURES
Mice
AMPKa1-deficient (Prkaa1/), T cell AMPKa1-deficient (Prkaa1fl/fl) and
Raptor-deficient (Rptrfl/fl), Tcrb/, Rag2/, OT-I, and C57BL/6-Ly5.1 mice
were bred and maintained under specific pathogen-free conditions at McGill
University under approved protocols.
T Cell Purification and Culture
CD4+ and CD8+ T cells were purified from spleen and peripheral lymph nodes
by negative selection and cultured in T cell medium (TCM) containing IMDM
supplemented with 10% FBS, L-glutamine, penicillin-streptomycin, and 2-
ME as previously described (Jones et al., 2007; MacIver et al., 2011). For
nutrient limitation conditions and SITA experiments, cells were cultured in
TCM containing 10% dialyzed FBS.
Flow Cytometry
Single-cell suspensions were stained with fluorescently conjugated Abs as
previously described (Jones et al., 2007; MacIver et al., 2011). Antigen-specific
CD8+ T cells were quantified using H2-KbOVA257–264 (K
b/OVA) or H-2Db-NP
tetramers. Cell viability was assessed using the Fixable Viability Dye eFluor
780 (eBioscience). ICS was performed using specific fluorochrome-labeled
mAbs (eBioscience) and flow cytometry as previously described (MacIver
et al., 2011). For 2-NBDG uptake in vivo, mice were injected intravenously
(i.v.) with 100 mg 2-NBDG/mouse 15 min prior to analysis (O’Sullivan et al.,
2014). Flow cytometry was performed on a Gallios or LSR II flow cytometer
and analyzed with FlowJo software.
Metabolic Assays
OCR, ECAR, and SRC were determined using a Seahorse XF96 Extracellular
Flux Analyzer following established protocols (Chang et al., 2013). ATP levels
were determined using CellTiter-Glo Luminescent Cell Viability reagent
(Promega). GC-MS- and LC-MS-based metabolomics studies were per-
formed using previously described methods (Dupuy et al., 2013; Faubert
et al., 2013). For SITA experiments, T cells were cultured with [U-13C]-glucose
or [U-13C]-glutamine (Cambridge Isotope Laboratories) for 0.5–6 hr. Mass iso-
topomer distribution was determined using a custom algorithm developed at
McGill University (McGuirk et al., 2013).
Immunoblotting and Quantitative Real-Time PCR
Immunoblotting and qPCR were conducted as previously described (MacIver
et al., 2011). Protein lysates were generated using AMPK Lysis Buffer supple-
mented with protease and phosphatase inhibitors (Faubert et al., 2013). Pri-
mary and secondary Abs and qPCR primer sets are listed in Supplemental
Experimental Procedures.
Adoptive Transfers and Infection Models
For development of T cell-mediated colitis, CD4+CD25 T cells were trans-
ferred into Tcrb/ or Rag2/ recipient mice, and inflammatory infiltration
into the cLP assessed 21 days later by flow cytometry and histological exam-
ination of H&E stained colon sections. Cytokine production in the mLN and
cLP was determined by ICS. Histopathological scoring is described in Sup-
plemental Experimental Procedures. Influenza A virus (IAV) infections were
performed with mouse-adapted IAV H1N1 strain A/Puerto Rico/8/34 (PR8)
as previously described (Coulombe et al., 2014). Mice were injected intrave-
nously with a sublethal dose of rLmOVA (5 3 104 cfu/ml) as described (Jones
et al., 2007). Mice were sacrificed 7 dpi, and splenocytes analyzed for the
presence of OVA-specific CD8+ T cells, cytokine production by CD4+ and
CD8+ T cells by ICS, or CD8+CD44hiCD62Llo cells sorted for metabolic
assays.
Statistical Analysis
Data are presented as mean ± SD for technical replicates, or mean ± SEM for
biological replicates. Statistical significance is indicated in all figures by the
following annotations: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2014.12.030.
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